GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (OSTO:XSPRAY) » Definitions » Total Equity

XSpray Pharma AB (OSTO:XSPRAY) Total Equity : kr623.10 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is XSpray Pharma AB Total Equity?

XSpray Pharma AB's total equity for the quarter that ended in Dec. 2024 was kr623.10 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

XSpray Pharma AB Total Equity Historical Data

The historical data trend for XSpray Pharma AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Total Equity Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 582.59 591.75 556.02 693.41 623.10

XSpray Pharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 693.41 625.16 668.14 585.59 623.10

XSpray Pharma AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

XSpray Pharma AB's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=796.344-173.247
=623.10

XSpray Pharma AB's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=796.344-173.247
=623.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XSpray Pharma AB Total Equity Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

XSpray Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (OSTO:XSPRAY) » Definitions » Total Equity
Comparable Companies
OSTO:EGTX OSTO:GENO OSTO:SANION OSTO:SYNACT OSTO:VICO OSTO:DMYD B XSAT:HAMLET B OSTO:HNSA OSTO:IBT B OSTO:BINV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
0GHZ:UK
Address
Scheeles vag 2, Solna, SWE, SE-171 65
Website
https://www.xspraypharma.com
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.

XSpray Pharma AB Headlines

No Headlines